We are live on ! Find out more
SLNO

Soleno Therapeutics
SLNO

Delisted

SLNO was delisted on the 15th of May, 2026.

Back to rankings

5 hedge funds and large institutions have $2.62M invested in Soleno Therapeutics in 2015 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

261% more capital invested

Capital invested by funds: $727K → $2.62M (+$1.89M)

0% more funds holding

Funds holding: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

1.81% less ownership

Funds ownership: 7.26% → 5.45% (-1.8%)

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$135K
2
Jane Street
Jane Street
New York
+$67.4K
3
BG
Bollard Group
Massachusetts
+$52.8K
4
Citigroup
Citigroup
New York
+$4.45K

Top Sellers

Rank Fund Capital Flow
1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$174K
2
RCM
Riverloft Capital Management
Florida
-$37K
3
UBS Group
UBS Group
Switzerland
-$3K
4
TRCT
Tower Research Capital (TRC)
New York
-$1.78K

SLNO Hedge Fund Activity: Q1 2015 in Review

5 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2015, worth a combined $2.62M — up 261% from $727K a quarter earlier.

Fund positioning in SLNO was balanced in Q1 2015: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $135K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $174K sold.

  • 5 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2015, unchanged from Q4 2014.
  • Funds reported $2.62M of Soleno Therapeutics stock for Q1 2015, up 261% quarter-over-quarter.
  • 3 funds opened new Soleno Therapeutics positions in Q1 2015 and 3 closed out, a net change of 0 holders.
  • The largest Soleno Therapeutics buyer in Q1 2015 was Vanguard Group, an estimated $135K added.
  • The largest Soleno Therapeutics seller in Q1 2015 was Hudson Bay Capital Management, an estimated $174K sold.

Based on aggregated 13F filings for Q1 2015.